{"nctId":"NCT05372653","briefTitle":"A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis","startDateStruct":{"date":"2022-05-23","type":"ACTUAL"},"conditions":["Atopic Dermatitis (AD)"],"count":41,"armGroups":[{"label":"OPA-15406","type":"EXPERIMENTAL","interventionNames":["Drug: OPA-15406"]}],"interventions":[{"name":"OPA-15406","otherNames":["difamilast"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who are diagnosed with AD in accordance with the criteria of the Japanese Dermatological Association\n* Subjects whose AD affects 5% to 40% of BSA (excluding scalp) at the screening and baseline examinations\n* Subjects who have an IGA score of 2 or 3 at the screening and baseline examinations\n\nExclusion Criteria:\n\n-Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification of AD, within 28 days prior to the baseline examination","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Months","maximumAge":"2 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Success Rate in IGA (Percentage of Subjects With an IGA Score of 0 or 1 With Improvement by at Least 2 Grades)","description":"The investigator or sub investigator assessed the skin symptoms using IGA (Investigator's Global Assessment). The investigator or sub investigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA was defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and had improved by at least 2 grades (responders) from baseline.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate in Eczema Area and Severity Index (EASI) 75 (Improvement of ≥75% in EASI)","description":"Response (improvement) in EASI 75 was defined as a decrease by ≥75% in the percent change from baseline in the total score of EASI.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.93","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":41},"commonTop":["Nasopharyngitis","Gastroenteritis","Dermatitis contact","COVID-19","Dermatitis diaper"]}}}